← All trials
NCT05490030
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2023
- Primary completion
- Jun 19, 2023
- Completion date
- Jun 19, 2023
- First posted
- Aug 5, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovartisLead sponsor
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.